Nivolumab Plus Cabozantinib in Non–Clear Cell RCC

David A. Braun, MD, PhD, highlights recent data focused on nivolumab plus cabozantinib in patients with non–clear cell renal cell carcinoma.

Related Keywords

,Advanced Renal Cell Carcinoma ,Plus Cabozantinib ,Clear Cell ,Advanced Rcc ,Nrcc ,Renal Cell Carcinoma ,Non Clear Cell Rcc ,Non Clear Cell Renal Carcinoma ,Cabozantinib ,Nivolumab ,